1. Home
  2. ABUS vs CGBD Comparison

ABUS vs CGBD Comparison

Compare ABUS & CGBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.31

Market Cap

929.6M

Sector

Health Care

ML Signal

HOLD

Logo Carlyle Secured Lending Inc.

CGBD

Carlyle Secured Lending Inc.

HOLD

Current Price

$11.25

Market Cap

826.2M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ABUS
CGBD
Founded
2005
2012
Country
United States
United States
Employees
N/A
2500
Industry
Biotechnology: Pharmaceutical Preparations
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
929.6M
826.2M
IPO Year
2008
N/A

Fundamental Metrics

Financial Performance
Metric
ABUS
CGBD
Price
$4.31
$11.25
Analyst Decision
Strong Buy
Hold
Analyst Count
1
8
Target Price
$5.00
$12.92
AVG Volume (30 Days)
1.7M
714.1K
Earning Date
05-14-2026
05-11-2026
Dividend Yield
N/A
14.42%
EPS Growth
55.26
N/A
EPS
0.87
N/A
Revenue
$14,083,000.00
N/A
Revenue This Year
N/A
$3.74
Revenue Next Year
$239.71
$1.80
P/E Ratio
$4.95
$10.36
Revenue Growth
128.21
N/A
52 Week Low
$3.04
$10.64
52 Week High
$5.10
$14.48

Technical Indicators

Market Signals
Indicator
ABUS
CGBD
Relative Strength Index (RSI) 47.54 43.92
Support Level $4.17 $11.19
Resistance Level $4.62 $11.44
Average True Range (ATR) 0.16 0.31
MACD 0.00 -0.08
Stochastic Oscillator 55.66 14.09

Price Performance

Historical Comparison
ABUS
CGBD

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

About CGBD Carlyle Secured Lending Inc.

Carlyle Secured Lending Inc is a specialty finance company that is a closed-end, externally managed, non-diversified management investment company. It focuses on providing directly originated, financing solutions across the capital structure, with a focus on senior secured lending to middle-market companies located in the United States. The company's investment objective is to generate current income and capital appreciation through debt investments in U.S. middle-market companies.

Share on Social Networks: